Life Science Nation Newsletter  |  January 7, 2016  |  Issue 145

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Dec. 31 - Jan. 6)
Invests to Address Health-Wealth Gap
Seeks IPO-Ready Life Science Companies
Focuses On Novel Ophthamology Technologies
Invests in Preclinical & Clinical-Stage Orphan Drugs
In This Issue
LSN Videos
RESI Boston 2015 Investors Panel

Video Recap of RESI@TMCx 2015

By Dennis Ford, Founder & CEO, LSN

With LSN's Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees. 

The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, we've reached capacity at our venue. We're therefore unable to take any more registrations.

However, here's the program guide; we hope that if you didn't make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If you'd like to attend a future RESI event, plan early!

Who Will You Meet at RESI San Francisco? 
By Cole Bunn, Research Analyst, LSN

Life Science Nation's mission of connecting scientist entrepreneurs with capital gave rise to the Redefining Early Stage Investments (RESI) conference nearly 3 years ago. As we approach our seventh RESI conference, during the highly anticipated JP Morgan week in San Francisco, we're expecting a record of well over 300 investors representing over 200 different firms in attendance.Figure 1 shows a breakdown of investors by type who will be at RESI San Francisco on January 12, 2016. You can also view the firms represented here.

Redefining Early Stage Investments (RESI) Conference: Corporate VCs & Strategic Investment Panel
By Christine A. Wu, Research Analyst, LSN

At LSN's RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.

In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they're interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.

Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:
  • Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
  • Geeta Vemuri, Vice President, Head, Baxalta Ventures
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Ilan Zipkin, Senior Investment Director, Takeda Ventures